Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer. 1998

E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
Department of Urology and Ludwig Boltzmann Institute for Urology and Andrology, Lainz Hospital Vienna, Austria.

The tissue concentrations of urokinase-type plasminogen activator (u-PA), urokinase-type plasminogen activator receptor (u-PAR), plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were investigated by an ELISA technique in normal and malignant samples of the prostate from 24 patients undergoing radical prostatectomy for organ-confined prostate cancer. The median concentration of u-PA was significantly higher in cancerous than in normal prostate tissue (p = 0.006). No significant increase of u-PAR, PAI-1 and t-PA was found in cancer tissue in comparison with the benign samples (p > 0.05). Assessment of the relationship between fibrinolytic proteins and DNA ploidy revealed an increased u-PA, u-PAR and PAI-1 in diploid prostate cancer as compared with the normal controls. However, in aneuploid cancer u-PA remained high but u-PAR and PAI-1 were decreased. This led to a higher local concentration of u-PA in aneuploid samples than in normal prostate and in diploid prostate cancer. No alteration of median t-PA was found in benign prostate or in diploid or aneuploid prostate cancer. The altered expression of u-PA, u-PAR and PAI-1 in diploid and aneuploid prostate cancer suggests a possible role of fibrinolytic proteins in the different biologic behavior of tumors, and may be one explanation for the higher metastatic potential of aneuploid tumors.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA

Related Publications

E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
January 1992, Cancer treatment and research,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
September 2005, JAMA,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
December 1989, Urology,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
June 1992, Analytical and quantitative cytology and histology,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
January 1992, The Prostate. Supplement,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
January 1996, European urology,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
December 2023, Cancer reports (Hoboken, N.J.),
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
August 1991, Cancer research,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
April 2003, Pathologica,
E Plas, and V A Carroll, and R Jilch, and J Mihaly, and M Vesely, and W Ulrich, and H Pflüger, and B R Binder
November 1999, Cancer control : journal of the Moffitt Cancer Center,
Copied contents to your clipboard!